The abstract is read at the publisher; the summary is JClub's.
PSIRC3, a covalent PROTAC for Bruton’s tyrosine kinase (BTK), degrades BTK with DC50 = 0.75 nM and Dmax = 85%, unlike its non-covalent counterpart.
- Why it matters: Covalent PROTACs are debated because irreversible binding appears to conflict with the catalytic degradation mechanism, limiting confidence in their therapeutic viability.
- What they did: The study developed PSIRC3 and tested BTK degradation in cells, showing dependence on covalent bond formation with Cys481 and loss of efficacy against the C481S BTK mutant.
- The result: PSIRC3 reached maximum BTK degradation within 30 min and, after single dosing in vivo, reduced BTK in PBMCs (>80%) and splenocytes (>50%), with modeling linking efficacy to E3–target affinity balance.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.